Oxford Nanopore Technologies plc Approval of the transfer of listing category

RNS Number : 0058L

Oxford Nanopore Technologies plc

06 November 2024

 

​THIS ANNOUNCEMENT DOES NOT CONSTITUTE A PROSPECTUS OR PROSPECTUS EQUIVALENT DOCUMENT AND NEITHER THIS ANNOUNCEMENT NOR ANYTHING HEREIN FORMS THE BASIS FOR ANY OFFER TO PURCHASE OR SUBSCRIBE FOR ANY SHARES OR OTHER SECURITIES IN THE COMPANY NOR SHALL IT FORM THE BASIS FOR ANY CONTRACT OR COMMITMENT WHATSOEVER.

6 November 2024

Oxford Nanopore Technologies plc

Approval of the transfer of listing category

Further to the announcement on 8 October 2024, Oxford Nanopore Technologies plc is pleased to announce the approval by the Financial Conduct Authority (the "FCA") of the transfer of  listing category of its ordinary shares from the equity shares (transition) category to the equity shares (commercial companies) category on the official list of the FCA, in accordance with Rule 21.5 of the UK Listing Rules as modified by Transitional Provision 2 (the "Transfer").

The Transfer will take effect at 8:00 a.m. GMT today.

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:         [e-mail]

Media:              [e-mail]

 

Citigroup Global Markets Limited (Joint Corporate Broker and Sponsor)

Robert Way

Richard Abel

Patrick Evans

[phone]

 

Teneo (communications adviser to the Company)

Tom Murray

Olivia Peters

[phone]

[e-mail]

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer.  Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.

 

For more information please visit: www.nanoporetech.com

 

Forward-looking statements

This announcement contains certain forward-looking statements. For example, statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as "aim", "plan", "expect", "intend", "anticipate", "believe", "estimate", "target", and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition, and by definition address matters that are, to different degrees, uncertain. Our results could be affected by macroeconomic conditions, the COVID-19 pandemic, delays in our receipt of components or our delivery of products to our customers, suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen surveillance. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

REAFLFLILFLEIIS